Alpelisib Efficacy without Cherry-PI3King Mutations

The PI3K inhibitor alpelisib is clinically approved for the treatment of metastatic estrogen receptor-positive breast cancers harboring hotspot mutations in PIK3CA, which encodes a subunit of PI3K. Prospective clinical trial results demonstrated benefit from alpelisib for the treatment of advanced E...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2023-03, Vol.29 (6), p.989-990
Main Authors: Tau, Steven, Miller, Todd W
Format: Article
Language:English
Subjects:
Biology
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Class I Phosphatidylinositol 3-Kinases - genetics
Female
Humans
Mutation
Phosphatidylinositol 3-Kinases - genetics
Prospective Studies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The PI3K inhibitor alpelisib is clinically approved for the treatment of metastatic estrogen receptor-positive breast cancers harboring hotspot mutations in PIK3CA, which encodes a subunit of PI3K. Prospective clinical trial results demonstrated benefit from alpelisib for the treatment of advanced ER+ breast cancers harboring PIK3CA mutations in the hotspots of exons 7, 9, and 20. However, 20% of PIK3CA mutations occur in non-hotspot regions. A recent article demonstrated that patients with cancers bearing non-hotspot PIK3CA mutations also derived benefit from alpelisib, which will inform clinical decision-making moving forward. See related article by Rugo et al., p. 1056.
ISSN:1078-0432
1557-3265
1557-3265
DOI:10.1158/1078-0432.CCR-22-3411